Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

View:
Post by WalkOverTheStrt on Mar 14, 2021 3:14pm

When will

IMO as long as Antibe is on a CA exchange the share price will come no where close to where most biotechs with a PH3 drug are valued ($600M+ minimum of ocurse IMO)  let alone one that could reach $4B annual sales....  

Dan can talk about waiting for the right time (wind in their sails) but I'd rather have European, USA, Japan, etc. partners signed while on the NASDAQ... market has a short memory and momentum while on the exchange is imperative. 

Also any buyout is not going to reach the potential $4B we all hope for unless the stock price is within the typical 60%-100% premium that BoDs approve. No board is going to approve some 200%+ premium, they would be voted out by SHs at next opportunity..

Antibe needs the stock price to appreciate and frankly we are fooling oursleves if we think it will be trading anywhere need there while being on this backwater exchange.
Comment by MrMugsy on Mar 14, 2021 3:40pm
With the discussions I've had with Management, I don't think anyone is arguing against the desire to be on a U.S. Exchange.  I don't think they're arguing that they want to be on a U.S. Exchange when such an OTENA deal occurs or if we are lucky enough to sell the entire business. But ... I don't think we're near a deal with Big Pharma yet.  Therefore, we don' ...more  
Comment by 123ABC on Mar 14, 2021 4:17pm
In other words, we'll die of old age before this stock does anything.
Comment by MrMugsy on Mar 14, 2021 4:53pm
Not necessarily. Phase 3 enabling application to be submitted at some point here. Other news to follow as well. Excitement likely to follow as FDA hurdles are jumped and the countdown to P3 begins. IMO
Comment by woundedknee on Mar 15, 2021 6:50am
Mugsy, have to respectfully disagree with you and agree 100 % with WalkOver. Your thinking doesn't appear tp be your own, but managements.  Case in point..Sigilon VS. Sernova. Sernova is light years ahead of Sigilon, but the big difference in market cap is only because of the difference in the two exchanges. Anyone interested in my point can go to the SVA board and read the article posted ...more  
Comment by 123ABC on Mar 15, 2021 7:13am
He definitely seems to be drinking that management Kool-Aid
Comment by MrMugsy on Mar 15, 2021 9:04am
No - my thoughts - not related to this management or any other management ... except for the experiences I've had. Yes - I have seen success outside the NASDAQ - that is absolutely true. As you will recall, I do want to go to a US exchange - and it will eventually happen.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities